

mk C7CO

04-12-02

1615 #6

PATENT
Attorney Docket No. 5052
Express Mail Label No. EV 010522412 US



04-19-02

RECEIVED
APR 15 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re The Application of:)	
C. Michael Philbrook et al.)	
)	Examiner: Not Yet Assigned
Serial No.: 10/033,274)	
)	Art Unit: 1615
Filed: December 27, 2001)	
For: Controlled Release of Anti-)	
Arrhythmic Agents)	

Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement herewith is being filed before the mailing of a first Office Action on the merits.

Applicants submit form PTO-1449 for consideration under CFR § 1.97(b) along with copies of the references listed #1-19.

Applicants believe that no fee is due with this submission.

U.S.S.N.: 10/033,274
Filed: December 27, 2001
INFORMATION DISCLOSURE STATEMENT

However, if any additional fees are required, the Commissioner is authorized to charge the said fees to Deposit Account No. 07-1074.



Respectfully submitted,

A handwritten signature in black ink, appearing to read "Isabelle A. S. Blundell".

Date: April 11, 2002

Isabelle A. S. Blundell, Ph.D.
Attorney for Applicants
Registration No. 43,321

GENZYME CORPORATION
Legal Department
One Kendall Square
Cambridge, Massachusetts 02139
Tel. (617) 591-5698
Fax. (617) 252-7977

EV010522412US